Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-Label, Phase 2 Basket Study of Neratinib in Patients With Solid Tumors With Somatic Activating HER Mutations

NCT01953926 is registered in ClinicalTrials.gov with Puma Biotechnology, Inc. as lead sponsor.

NCT NCT01953926
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01953926 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-Label, Phase 2 Basket Study of Neratinib in Patients With Solid Tumors With Somatic Activating HER Mutations
Lead sponsor
Puma Biotechnology, Inc.
Phase
Phase 2
Overall status
Terminated
Start date
September 30, 2013
Completion date
January 2, 2023
Enrollment
582 (actual)
Sites
60

Conditions

As the registry lists them; a condition with its own page is linked.

solid tumors harboring somatic her2 or egfr exon 18 mutations